CD8A and neoplasm: P16 shows more attenuated or absent expression in the group of patients with CDKN2A mutations, and similarly, the percentage of tumor-infiltrating lymphocytes with positivity for the CD8 immunohistochemical antibody is lower in the group of patients with homo- and heterozygous deletions of CDKN2A, compared to the results obtained in the subgroup of monosomies and disomies.